Abcam Share Discussion Threads

[wjccghcc] 19/9/2007 09:12

Likewise, it was a calculated risk and I'm happy to hold them. Bid is now at 310p which is where it was before the trading ahead of expectations statement. A cost of 5p to bet on a takeover premium of 80p was worth it IMHO.

[56richard] 19/9/2007 08:12

Oh well!! Other things to smile about today though - Im still positive about the company - lets see what the results bring.

[wjccghcc] 16/9/2007 19:54

I've added quite a few at 315-318p over the last few weeks. The price was pretty much back to where it was before the trading statement, let alone the bid.

[56richard] 14/9/2007 16:53

Well here we still are in this quiet backwater - avoiding the market turmoil (so far)with a successful growing company in a dominant market position with relatively few shares available and a possible bid on the horizon - is it too good to be true?

[56richard] 30/7/2007 20:31

Have they been approached? or are they trying to attract buyers? (or both). I have taken a bit of a punt and topped up a little today anyway.

[crazycoops] 27/7/2007 15:58

And only a 10% increase on the day. I would imagine a successful bid would have to be at least 30% premium, especially as it appears there is more than one bidder.

[goatman] 27/7/2007 09:32

Hi everyone!

Are there amy holders? Possible offer for the Co and not a murmer on here!

G

[56richard] 30/6/2007 11:24

Not putting a foot wrong at the moment! (I also hold character Group and they put out a trading statement a little while ago saying they will 'significantly exceed' market expectations with no figure put on 'significantly exceed' - consequently everyone piled in expecting something extra amazing on results day only to be dissapointed by what would otherwise have been excellent figures! They are not falling into same trap here) - just quietly confident with good news. Fingers crossed anyway!

[hazelton] 16/4/2007 07:05

My original interest in ABCAM was that its held by the Keydata AIM VCT , with the highly rated Giles Hargraeves as manager. If its good enough for him then they were good enough for me.

[56richard] 15/4/2007 12:34

A bit out of date (25 March 2007) but just found this - every little helps!:

The Unicorn Outstanding British Companies fund aims to identify the very best of British companies - and stick with them. The 40 or so companies in its portfolio will be held for at least five years and more likely 10 years or more. 'Short-termism is an ever-present problem,' said Chris Hutchinson, who manages the fund with Peter Webb. 'There is too much churn. Yet the long-term statistics show that a big component of total return comes from dividends [which come from holding shares].'
The investments are chosen on 10 key criteria, including predictability of earnings and cashflow; companies in growing markets and with competitive advantage; a good track record; and low borrowings. They can come from anywhere on the market, from the FTSE 100 corporate giants - like credit-checking business Experian, worth £6bn - to the tiddlers of the AIM. The smallest company is Gooch & Housego, which makes optical products and is valued at £79m.

In fact, Unicorn's top five holdings are relatively small - Domino's Pizza, Domino Printing, Italian cafe and deli chain Carluccio's, Datamonitor and Abcam. The latter, says Hutchinson, is typical of the kind of attributes he looks for: a manufacturer and distributor of antibodies for research and pharmaceutical companies, it has built up a dominant global position through its internet presence.

[wjccghcc] 22/2/2007 09:14

Sold a few first thing but only because I thought the recent share price spike had got ahead of itself. Q2 growth was a bit dissappointing but they imply it will pick up again in Q3. Good management, good potential. Happy to keep my core holding.

[benson] 22/2/2007 09:09

I am v surprised at the reaction to the results. This is a thinly traded share so a couple of sells at 8am will scare the MMs - or perhaps a large delayed sell is yet to be reported. I remain a holder.

[analyst] 22/2/2007 09:06

RESULTS DAY

Sales in the half year increased 34% to #11.1m (H1 2005-06: #8.3m)

Pre-tax profits increased 18% to #2.4m (H1 2005-06: #2.0m)

Net cash at 31 December 2006 of #10.7m (31 December 2005: #10.8m)

Proposed interim dividend up 14% to 0.8p per share (H1 2005-06: 0.7p)

Share price down 9%

A bargain.

[hazelton] 22/2/2007 07:44

ABCAM Plc
22 February 2007


For immediate release 22 February 2007


ABCAM PLC
('Abcam' of 'the Company')

Acquisition of Exclusive Distribution Rights
of a minimum of 3,500 antibodies over 5 years


Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets
antibodies via its own online catalogue, is pleased to announce that it has
entered a joint agreement with Assay BioTechnology Company Inc. ('ABT') and Anbo
Biotechnology ('Anbo') to acquire exclusive worldwide rights for the
distribution of the two companies' entire product portfolio of research
antibodies to be sold under the Abcam brand.

This acquisition is in line with the Company's strategy of expanding its
antibody catalogue both organically and by acquisition and follows the
successful acquisition in August 2006 of exclusive distribution rights from
Triple Point Biologics Inc.

ABT, a privately owned US company founded in 2003 and based in California,
tests, validates and markets research antibodies developed and produced by Anbo,
also privately owned, at a 30,000 sq ft purpose-built building in Chang Zhou
City, China.

Prior to this acquisition, Abcam was already selling some 250 of ABT's products
on a non-exclusive basis and their good performance and high quality led Abcam
to seek a wider and closer longer-term relationship. Under the terms of the deal
the 250 products will become exclusive and Abcam will immediately add a further
250 products on an exclusive basis. ABT are committed to adding a minimum of 600
new products in each of the next 5 years, bringing the total number of products
included in the deal to at least 3,500.

Details of the financial terms of the deal are confidential, although royalties
to be paid are in line with other such agreements. The deal will be funded out
of the Company's existing cash resources and Abcam will have an option to
acquire the product range outright.

Jonathan Milner, Abcam's Chief Executive Officer, said: 'ABT's products include
good quality, high demand, modification-state antibodies as well as a number of
assay kits that fit within Abcam's popular nuclear signalling and chromatin
range. We are particularly excited about these, since the study of modified
proteins is gaining momentum as their increasing role in health and disease is
recognised. It is expected that the deal will be earnings enhancing in the
financial year to June 2008.'



For further information please contact:

Abcam plc + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Eddie Powell, Chief Financial Officer + 44 (0) 1223 696000
www.abcam.com

Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Mary-Jane Johnson




Notes for editors


About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered
in Cambridge, UK, with a US office located in Cambridge, Massachusetts. Abcam
was admitted to AIM in November 2005 and trades under the ticker symbol ABC.
The Company produces and distributes its own and third party produced antibodies
to academic and commercial users throughout the world with product information
provided and ordering available through the Company's website, www.Abcam.com.
The antibodies are sold under the Abcam brand name. The Company's vision is to
build the largest online antibody resource in the world while also ensuring that
the antibodies are of high quality and commercially viable. Abcam now has an
online catalogue of 29,000 products, most of which are antibodies, from over 200
suppliers supported by up-to-date and detailed technical data sheets, which are
created by the Company. The Company currently employs 120 staff in its three
operating companies


About antibodies

Antibodies are proteins produced by white blood cells in response to the
introduction of a foreign body known as an antigen. Antibodies, which have a
wide variety of uses in research, diagnostics and therapeutics, are used by
bioscientists in research into disease and into the human genome, where they are
used to mark and identify specific cells and other living matter. The number of
human antibodies of use in research is potentially greater than one million.




This information is provided by RNS
The company news service from the London Stock Exchange

[analyst] 20/2/2007 18:51

Onwards & upwards.

[benson] 19/2/2007 08:31

For those who trade breakouts, le voila!

[benson] 14/2/2007 15:36

Has broken out.

[benson] 14/2/2007 10:43

Trying to breakout.

[56richard] 30/1/2007 17:00

I like abcam - and have been adding little by little (sure sign of a dramatic fall!!). They seem to have a clear and very focused model (and market) - also a style which is an antidote to most big business shares i hold! Lots seems to be happening too. Fingers crossed

[hazelton] 29/12/2006 13:29

A little movement I think

[quickmind] 23/12/2006 11:31

Abcam and Tepnel up on licensing deal
Kam Patel, 21/12/06 15:04

The market welcomed a deal that will see Abcam, which markets antibodies, distribute pharma group Tepnel's range of diagnostic and research products. Under the terms of the deal, Abcam, which bills itself as the world's largest online supplier of antibody products, will distribute Tepnel's Diaclone range. The range includes more than 350 immunological products designed for therapy, diagnostic and research applications.

The distribution deal is exclusive for sales into Japan, Canada, and South America. In the USA, Abcam will share the sales rights for the Diaclone range with Tepnel. The arrangement is non-exclusive elsewhere in the world. As part of the agreement, Abcam will give Tepnel an upfront payment - not disclosed in the statement - and has guaranteed to a minimum level of annual sales.

Both parties hailed the deal, with Tepnel saying the move significantly extends its reach and will provide it immediate access to a broad range of customers from both academia and industry. Tepnel adds that the Diaclone range is already one of the world's leading sources of immunological products and with the new partnership in place, it should be able to further extend its market share in the area.

Abcam, meanwhile, says it is 'excited' about the agreement as it will allows it to expand its product range into antibody related products for sale across an already wide geographical footprint. The deal pleased the market, with Abcam shares Plc shares rising 12p or 5% by midday to 260p, valuing the company at £90m; as Tepnel Life Science Plc put on 0.38p to 8.12p, valuing it at £17.8m.

Abcam's housebroker Numis welcomes the deal as it will enable the group to expand its product range. However, looking ahead over next 12 months, it believes the big focus for investors will be Abcam's progress with expansion into Japanese market and updates on how it is getting on with the building of a new, high throughput laboratory. The group unveiled plans to build the new 20,000 square feet facility at its AGM in October. It will allow Abcam to identify and produce 25,000-50,000 antibodies in-house within the next six years. That would give rise to additional turnover of £20-30m.

At the AGM, Abcam chairman David Cleevely said that in-house antibodies, which offer higher margins than those bought in, now make up roughly 15%. Cleevely also revealed that first quarter sales were up by 44% year-on-year, and noted that investment in the new lab will hit post-tax profits by £200,000-300,000 in the current financial year.

Abcam, a spin off from Cambridge University, posted full year to 30 June sales of £19.4m. It listed on the AIM market last in November 2005 via a placement of just over £15m. Numis says the announcement today underpins its current forecasts and it is therefore maintaining its estimates for 2007 and 2008, with a target price of 264p. It rates the stock a 'hold'.

The broker has pencilled full year 2007 pretax profits of £5.1m on sales of £26m, with earnings per share seen coming in at 11p alongside a dividend of 2.9p. For 2008 it estimates pretax profits of £5.9m on sales of £33m, with earnings per share of 13p and a dividend of 3.3p. Abcam trades on a 2007 forward multiple of 23.6, falling to 20 in 2008. The prospective yield is 1.1%.

[analyst] 21/12/2006 09:00

Signs of life here - this company has a fantastic reputation for those in the market for its products - a new distribution deal announced today.